226 related articles for article (PubMed ID: 19155993)
21. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.
Johnston C; Saracino M; Kuntz S; Magaret A; Selke S; Huang ML; Schiffer JT; Koelle DM; Corey L; Wald A
Lancet; 2012 Feb; 379(9816):641-7. PubMed ID: 22225814
[TBL] [Abstract][Full Text] [Related]
22. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.
Gupta R; Wald A; Krantz E; Selke S; Warren T; Vargas-Cortes M; Miller G; Corey L
J Infect Dis; 2004 Oct; 190(8):1374-81. PubMed ID: 15378428
[TBL] [Abstract][Full Text] [Related]
23. Patterns of herpes simplex virus shedding over 1 month and the impact of acyclovir and HIV in HSV-2-seropositive women in Tanzania.
Tanton C; Weiss HA; LeGoff J; Changalucha J; Clayton TC; Ross DA; Belec L; Hayes RJ; Watson-Jones D
Sex Transm Infect; 2011 Aug; 87(5):406-11. PubMed ID: 21653932
[TBL] [Abstract][Full Text] [Related]
24. Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.
Kim HN; Wang J; Hughes J; Coombs R; Sanchez J; Reid S; Delany-Moretlwe S; Cowan F; Fuchs J; Eshleman SH; Khaki L; McMahon MA; Siliciano RF; Wald A; Celum C
J Infect Dis; 2010 Sep; 202(5):734-8. PubMed ID: 20649426
[TBL] [Abstract][Full Text] [Related]
25. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial.
Paz-Bailey G; Sternberg M; Puren AJ; Markowitz LE; Ballard R; Delany S; Hawkes S; Nwanyanwu O; Ryan C; Lewis DA
J Infect Dis; 2009 Oct; 200(7):1039-49. PubMed ID: 19715417
[TBL] [Abstract][Full Text] [Related]
26. Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels.
Nagot N; Ouedraogo A; Konate I; Weiss HA; Foulongne V; Defer MC; Sanon A; Becquart P; Segondy M; Sawadogo A; Van de Perre P; Mayaud P;
J Infect Dis; 2008 Jul; 198(2):241-9. PubMed ID: 18593294
[TBL] [Abstract][Full Text] [Related]
27. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
Wald A; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Fife K; Selke S; Huang ML; Stobernack HP; Zimmermann H; Corey L; Birkmann A; Ruebsamen-Schaeff H
JAMA; 2016 Dec; 316(23):2495-2503. PubMed ID: 27997653
[TBL] [Abstract][Full Text] [Related]
28. Health care seeking among men with genital ulcer disease in South Africa: correlates and relationship to human immunodeficiency virus-1 and herpes simplex virus type 2 detection and shedding.
Leichliter JS; Lewis DA; Sternberg M; Habel MA; Paz-Bailey G
Sex Transm Dis; 2011 Sep; 38(9):865-70. PubMed ID: 21844743
[TBL] [Abstract][Full Text] [Related]
29. Herpes Simplex Virus Suppressive Therapy in Herpes Simplex Virus-2/Human Immunodeficiency Virus-1 Coinfected Women Is Associated With Reduced Systemic CXCL10 But Not Genital Cytokines.
Andersen-Nissen E; Chang JT; Thomas KK; Adams D; Celum C; Sanchez J; Coombs RW; McElrath MJ; Baeten JM
Sex Transm Dis; 2016 Dec; 43(12):761-764. PubMed ID: 27832025
[TBL] [Abstract][Full Text] [Related]
30. Genital shedding of herpes simplex virus-2 DNA and HIV-1 RNA and proviral DNA in HIV-1- and herpes simplex virus-2-coinfected African women.
Mbopi-Kéou FX; Legoff J; Grésenguet G; Si-Mohamed A; Matta M; Mayaud P; Andreoletti L; Malkin JE; Weiss H; Brown D; Bélec L
J Acquir Immune Defic Syndr; 2003 Jun; 33(2):121-4. PubMed ID: 12794542
[No Abstract] [Full Text] [Related]
31. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
[TBL] [Abstract][Full Text] [Related]
32. Determinants of HIV type 1 shedding from genital ulcers among men in South Africa.
Paz-Bailey G; Sternberg M; Puren AJ; Steele L; Lewis DA
Clin Infect Dis; 2010 Apr; 50(7):1060-7. PubMed ID: 20178417
[TBL] [Abstract][Full Text] [Related]
33. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.
Schacker T; Zeh J; Hu H; Shaughnessy M; Corey L
J Infect Dis; 2002 Dec; 186(12):1718-25. PubMed ID: 12447756
[TBL] [Abstract][Full Text] [Related]
34. Real-time PCR quantification of genital shedding of herpes simplex virus (HSV) and human immunodeficiency virus (HIV) in women coinfected with HSV and HIV.
Legoff J; Bouhlal H; Grésenguet G; Weiss H; Khonde N; Hocini H; Désiré N; Si-Mohamed A; de Dieu Longo J; Chemin C; Frost E; Pépin J; Malkin JE; Mayaud P; Bélec L
J Clin Microbiol; 2006 Feb; 44(2):423-32. PubMed ID: 16455895
[TBL] [Abstract][Full Text] [Related]
35. Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial.
Baeten JM; McClelland RS; Corey L; Overbaugh J; Lavreys L; Richardson BA; Wald A; Mandaliya K; Bwayo JJ; Kreiss JK
J Infect Dis; 2004 Apr; 189(8):1466-71. PubMed ID: 15073684
[TBL] [Abstract][Full Text] [Related]
36. Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.
Roxby AC; Drake AL; Ongecha-Owuor F; Kiarie JN; Richardson B; Matemo DN; Overbaugh J; Emery S; John-Stewart GC; Wald A; Farquhar C
PLoS One; 2012; 7(6):e38622. PubMed ID: 22701683
[TBL] [Abstract][Full Text] [Related]
37. The effects of daily distress and personality on genital HSV shedding and lesions in a randomized, double-blind, placebo-controlled, crossover trial of acyclovir in HSV-2 seropositive women.
Strachan E; Saracino M; Selke S; Magaret A; Buchwald D; Wald A
Brain Behav Immun; 2011 Oct; 25(7):1475-81. PubMed ID: 21693182
[TBL] [Abstract][Full Text] [Related]
38. Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials.
Watson-Jones D; Wald A; Celum C; Lingappa J; Weiss HA; Changalucha J; Baisley K; Tanton C; Hayes RJ; Marshak JO; Gladden RG; Koelle DM
J Clin Microbiol; 2010 Oct; 48(10):3496-503. PubMed ID: 20702659
[TBL] [Abstract][Full Text] [Related]
39. Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial.
Bender Ignacio RA; Perti T; Magaret AS; Rajagopal S; Stevens CE; Huang ML; Selke S; Johnston C; Marrazzo J; Wald A
J Infect Dis; 2015 Dec; 212(12):1949-56. PubMed ID: 26044291
[TBL] [Abstract][Full Text] [Related]
40. Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy.
Tobian AA; Grabowski MK; Serwadda D; Newell K; Ssebbowa P; Franco V; Nalugoda F; Wawer MJ; Gray RH; Quinn TC; Reynolds SJ;
J Infect Dis; 2013 Sep; 208(5):839-46. PubMed ID: 23812240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
